Genmab A/S (NASDAQ:GMAB) Shares Acquired by Cromwell Holdings LLC

Cromwell Holdings LLC lifted its position in shares of Genmab A/S (NASDAQ:GMAB) by 656.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,876 shares of the company’s stock after purchasing an additional 2,496 shares during the period. Cromwell Holdings LLC’s holdings in Genmab A/S were worth $60,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in GMAB. Two Sigma Advisers LP grew its holdings in shares of Genmab A/S by 84.1% during the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after buying an additional 280,900 shares during the last quarter. ABC Arbitrage SA purchased a new position in shares of Genmab A/S during the fourth quarter worth about $3,692,000. Natixis Advisors LLC grew its holdings in shares of Genmab A/S by 29.8% during the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock worth $5,036,000 after buying an additional 47,437 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Genmab A/S by 229.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company’s stock worth $1,033,000 after buying an additional 34,652 shares during the last quarter. Finally, FMR LLC grew its holdings in shares of Genmab A/S by 13.5% during the third quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after buying an additional 33,076 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Trading Up 2.1 %

Shares of GMAB opened at $22.44 on Friday. Genmab A/S has a twelve month low of $18.64 and a twelve month high of $31.88. The stock’s 50 day moving average is $20.68 and its two-hundred day moving average is $22.97. The firm has a market capitalization of $14.85 billion, a PE ratio of 12.90, a P/E/G ratio of 2.57 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, sell-side analysts predict that Genmab A/S will post 1.45 EPS for the current year.

Analyst Ratings Changes

GMAB has been the topic of a number of research reports. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a report on Thursday, February 13th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Thursday, January 23rd. Finally, Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $42.17.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.